Yale trial aims to tame tough breast cancer with dual drug attack
NCT ID NCT06963905
Summary
This study is testing two different drug combinations for people with advanced triple-negative breast cancer that has worsened after one prior treatment. The goal is to see if adding a newer immunotherapy drug to an existing treatment is safe and can better control the cancer. About 60 participants will receive one of the two combinations until the cancer grows, side effects become too severe, or they choose to stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.